Progyny, Inc. $PGNY Shares Bought by Lazard Asset Management LLC

Lazard Asset Management LLC lifted its position in shares of Progyny, Inc. (NASDAQ:PGNY) by 91.6% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 63,264 shares of the company’s stock after acquiring an additional 30,247 shares during the quarter. Lazard Asset Management LLC owned 0.08% of Progyny worth $1,074,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of the company. OMERS ADMINISTRATION Corp increased its stake in Progyny by 53.5% in the 1st quarter. OMERS ADMINISTRATION Corp now owns 95,305 shares of the company’s stock valued at $1,618,000 after purchasing an additional 33,200 shares in the last quarter. Healthcare of Ontario Pension Plan Trust Fund purchased a new stake in Progyny during the first quarter worth $3,110,000. State of Wyoming boosted its position in Progyny by 18.2% during the first quarter. State of Wyoming now owns 37,822 shares of the company’s stock worth $642,000 after purchasing an additional 5,824 shares in the last quarter. First Trust Advisors LP boosted its position in Progyny by 26.2% during the first quarter. First Trust Advisors LP now owns 388,924 shares of the company’s stock worth $6,604,000 after purchasing an additional 80,743 shares in the last quarter. Finally, SEB Asset Management AB acquired a new stake in Progyny in the first quarter valued at $1,299,000. Institutional investors and hedge funds own 94.93% of the company’s stock.

Insider Activity at Progyny

In other Progyny news, CFO Mark S. Livingston sold 2,517 shares of the firm’s stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $25.50, for a total transaction of $64,183.50. Following the sale, the chief financial officer directly owned 74,688 shares of the company’s stock, valued at $1,904,544. This trade represents a 3.26% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Kevin K. Gordon sold 5,500 shares of Progyny stock in a transaction dated Wednesday, May 27th. The stock was sold at an average price of $24.99, for a total transaction of $137,445.00. Following the sale, the director owned 9,318 shares of the company’s stock, valued at approximately $232,856.82. This trade represents a 37.12% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 36,916 shares of company stock worth $939,875 over the last three months. Company insiders own 9.90% of the company’s stock.

Analyst Ratings Changes

PGNY has been the subject of a number of research analyst reports. Citizens Jmp raised their price target on Progyny from $30.00 to $31.00 and gave the company a “market outperform” rating in a research report on Monday, May 11th. Wall Street Zen cut shares of Progyny from a “strong-buy” rating to a “buy” rating in a research note on Saturday, July 25th. KeyCorp raised their target price on shares of Progyny from $30.00 to $35.00 and gave the company an “overweight” rating in a report on Monday, July 13th. Barclays restated an “equal weight” rating and set a $34.00 target price (up from $27.00) on shares of Progyny in a research report on Tuesday, July 28th. Finally, Weiss Ratings raised shares of Progyny from a “hold (c-)” rating to a “hold (c)” rating in a report on Friday, June 26th. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $33.25.

Progyny Stock Down 0.2%

NASDAQ PGNY opened at $31.48 on Wednesday. Progyny, Inc. has a fifty-two week low of $16.10 and a fifty-two week high of $33.06. The business has a fifty day moving average of $28.82 and a 200-day moving average of $23.31. The stock has a market cap of $2.47 billion, a price-to-earnings ratio of 40.88, a price-to-earnings-growth ratio of 2.50 and a beta of 1.01.

Progyny (NASDAQ:PGNY) last posted its quarterly earnings data on Thursday, May 7th. The company reported $0.50 EPS for the quarter, beating analysts’ consensus estimates of $0.26 by $0.24. The business had revenue of $328.50 million for the quarter, compared to analyst estimates of $326.46 million. Progyny had a return on equity of 13.34% and a net margin of 5.23%.The business’s revenue for the quarter was down 26.4% compared to the same quarter last year. During the same quarter last year, the company earned $0.17 earnings per share. Progyny has set its FY 2026 guidance at 1.980-2.09 EPS and its Q2 2026 guidance at 0.500-0.53 EPS. As a group, analysts anticipate that Progyny, Inc. will post 1.19 EPS for the current year.

Progyny declared that its Board of Directors has authorized a share repurchase program on Tuesday, May 26th that allows the company to buyback $200.00 million in outstanding shares. This buyback authorization allows the company to buy up to 10.3% of its shares through open market purchases. Shares buyback programs are often an indication that the company’s leadership believes its stock is undervalued.

Progyny Company Profile

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.